Status:
COMPLETED
Comparison of Quantitative Metamorphopsia- Measurements in Patients With mCNV
Lead Sponsor:
PD Dr. med. Katja Hatz
Conditions:
Metamorphopsia
Eligibility:
All Genders
Brief Summary
The myopic CNV (mCNV) is a blood vessel neoplasm starting from the choroid, based on pathological myopia (severe myopia). Choroidal neovascularization secondary to pathological myopia is the most com...
Detailed Description
The myopic CNV is a neovascularization starting from the choroid and growing into the space between choroid and retina, based on pathological myopia (severe myopia). Choroidal neovascularization secon...
Eligibility Criteria
Inclusion
- diagnosis of mCNV involving the juxtafoveal or/and foveal region
- BCVA \>0.1 (20/200, Snellen)
- ability to follow the study procedures
- given written consent to participation
- \>18 years
Exclusion
- history of vitreoretinal surgery (including membrane peeling and retinal detachment surgery) to the study eye
- presence of macula foramen or epiretinal membrane with significant distortion of retinal architecture
- history of any side effects to Tropicamide eye drops
Key Trial Info
Start Date :
October 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 2 2021
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04112524
Start Date
October 8 2019
End Date
February 2 2021
Last Update
December 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vista Klinik
Binningen, Basel-Landschaft, Switzerland, 4102